Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...
Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
Jay Olson, an analyst from Oppenheimer, maintained the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated price target ...
Viking Therapeutics CEO Brian Lian said: "The VENTURE-Oral Phase 2 study represents an important milestone for the VK2735 program, as we advance two formulations of this compound into later-stage ...
Viking Therapeutics (PRNewsfoto/Viking Therapeutics ... of this compound into later-stage development," said Brian Lian, chief executive officer of Viking Therapeutics. "Prior 28-day Phase ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback